Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Jonasch

Showing results (211-220 of 271) with videos related to

Pageof 28
Sort By:
Ophthalmology|February 22, 2025
CorrigendumHenry E Wiley, Ramaprasad Srinivasan, Jodi K Maranchie, et al.
Nature Communications|May 3, 2020
PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinomaXian-De Liu, Wen Kong, Christine B Peterson, et al.
BJU International|July 6, 2021
Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalationBrian De, Aradhana M Venkatesan, Pavlos Msaouel, et al.
Urologic Oncology|November 14, 2020
Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitorsJad Chahoud, Pavlos Msaouel, Jeremy A Ross, et al.
Journal for Immunotherapy of Cancer|July 30, 2021
Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse eventsBilal A Siddiqui, Jinesh S Gheeya, Rohit Goswamy, et al.
Journal for Immunotherapy of Cancer|December 21, 2019
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)Brian I Rini, Dena Battle, Robert A Figlin, et al.
Cancer Immunology Research|May 28, 2015
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell CarcinomaXian-De Liu, Anh Hoang, Lijun Zhou, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinomaKabir Grewal, Maria Julia Moura Nascimento Santos, Pankaj Kumar Chauhan, et al.
Nature Genetics|May 2, 2019
SETD2 regulates the maternal epigenome, genomic imprinting and embryonic developmentQianhua Xu, Yunlong Xiang, Qiujun Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2017
Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional LandscapeZixing Wang, Tae Beom Kim, Bo Peng, et al.
Pageof 28

Showing results (211-220 of 271) with videos related to

Sort By:
Pageof 28
Ophthalmology|February 22, 2025
CorrigendumHenry E Wiley, Ramaprasad Srinivasan, Jodi K Maranchie, et al.
Nature Communications|May 3, 2020
PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinomaXian-De Liu, Wen Kong, Christine B Peterson, et al.
BJU International|July 6, 2021
Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalationBrian De, Aradhana M Venkatesan, Pavlos Msaouel, et al.
Urologic Oncology|November 14, 2020
Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitorsJad Chahoud, Pavlos Msaouel, Jeremy A Ross, et al.
Journal for Immunotherapy of Cancer|July 30, 2021
Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse eventsBilal A Siddiqui, Jinesh S Gheeya, Rohit Goswamy, et al.
Journal for Immunotherapy of Cancer|December 21, 2019
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)Brian I Rini, Dena Battle, Robert A Figlin, et al.
Cancer Immunology Research|May 28, 2015
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell CarcinomaXian-De Liu, Anh Hoang, Lijun Zhou, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinomaKabir Grewal, Maria Julia Moura Nascimento Santos, Pankaj Kumar Chauhan, et al.
Nature Genetics|May 2, 2019
SETD2 regulates the maternal epigenome, genomic imprinting and embryonic developmentQianhua Xu, Yunlong Xiang, Qiujun Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2017
Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional LandscapeZixing Wang, Tae Beom Kim, Bo Peng, et al.
Pageof 28